|
1
|
Marmé F and Schneeweiss A: Targeted
therapies in triple-negative breast cancer. Breast Care.
10:159–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schmadeka R, Harmon BE and Singh M:
Triple-negative breast carcinoma: Current and emerging concepts. Am
J Clin Pathol. 141:462–477. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Elsamany S and Abdullah S: Triple-negative
breast cancer: Future prospects in diagnosis and management. Med
Oncol. 31:8342014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Merlin JL, Harlé A, Lion M, Ramacci C and
Leroux A: Expression and activation of P38 MAP kinase in invasive
ductal breast cancers: Correlation with expression of the estrogen
receptor, HER2 and downstream signaling phosphorylated proteins.
Oncol Rep. 30:1943–1948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bachmann C, Schmidt S, Staebler A, Fehm T,
Fend F, Schittenhelm J, Wallwiener D and Grischke E: CNS metastases
in breast cancer patients: Prognostic implications of tumor
subtype. Med Oncol. 32:4002015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ,
Yang JH, Park YH, Ahn JS and Im YH: Potential candidate biomarkers
for heterogeneity in triple-negative breast cancer (TNBC). Cancer
Chemother Pharmacol. 68:753–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lips EH, Mulder L, Oonk A, van der Kolk
LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S and Nederlof
PM: Triple-negative breast cancer: BRCAness and concordance of
clinical features with BRCA1-mutation carriers. Br J Cancer.
108:2172–2177. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J,
Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, et al: Cisplatin plus
gemcitabine versus paclitaxel plus gemcitabine as first-line
therapy for metastatic triple-negative breast cancer (CBCSG006): A
randomised, open-label, multicentre, phase 3 trial. Lancet Oncol.
16:436–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding
XY, Zhang P, Li Q and Cai RG: Doxetaxel cisplatin might be superior
to docetaxel capecitabine in the first line treatment of
metastastic triple negative breast cancer. Ann Oncol. 24:1219–1225.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gelmon K, Dent R, Mackey JR, Laing K,
McLeod D and Verma S: Target triple negative breast cancer:
Optimizing therapeutic outcomes. Ann Oncol. 23:2223–2234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Wang Z, Hu X, Wang B, Wang L,
Yang W, Liu Y, Liu G, Di G, Hu Z, et al: Cisplatin and gemcitabine
as the first line therapy in metastatic triple negative breast
cancer. Int J Cancer. 136:204–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taniguchi T, Tischkowitz M, Ameziane N,
Hodgson SV, Mathew CG, Joenje H, Mok SC and D'Andrea AD: Disruption
of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian
tumors. Nat Med. 9:568–574. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei M, Xu J, Dignam J, Nanda R, Sveen L,
Fackenthal J, Grushko TA and Olopade OI: Estrogen receptor alpha,
BRCA1, and FANCF promoter methylation occur in distinct subsets of
sporadic breast cancers. Breast Cancer Res Treat. 111:113–120.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jing MX, Mao XY, Li C, Wei J, Liu C and
Jin F: Estrogen receptor-alpha promoter methylation in sporadic
basal-like breast cancer of Chinese women. Tumor Biol. 32:713–719.
2011. View Article : Google Scholar
|
|
15
|
Taniguchi T, Kakkar AK, Tuddenham EG,
Williamson RC and Lemoine NR: Enhanced expression of urokinase
receptor induced through the tissue factor-factor via pathway in
human pancreatic cancer. Cancer Res. 58:4461–4467. 1998.PubMed/NCBI
|
|
16
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: NCCN guidelines insights breast cancer, version
1.2016. J Natl Compr Canc Netw. 13:1475–1485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seitz S, Rick FG, Schally AV, Treszl A,
Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB and Buchholz
S: Combination of GHRH antagonists and docetaxel shows experimental
effectiveness for the treatment of triple-negative breast cancers.
Oncol Rep. 30:413–418. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van de Water W, Seynaeve C, Bastiaannet E,
Markopoulos C, Jones SE, Rea D, Hasenburg A, Putter H, Hille ET,
Paridaens R, et al: Elderly postmenopausal patients with breast
cancer are at increased risk for distant recurrence: A tamoxifen
exemestane adjuvant multinational study analysis. Oncologist.
18:8–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Makubate B, Donnan PT, Dewar JA, Thompson
AM and McCowan C: Cohort study of adherence to adjuvant endocrine
therapy, breast cancer recurrence and mortality. Br J Cancer.
108:1515–1524. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in triple
negative breast cancer from two phase III randomized adjuvant
breast cancer trail: ECOG 2197 and ECOG 1199. J Clin Oncol.
32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schneider BP, Zhao F, Wang M, Stearns V,
Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, et
al: Neuropathy is not associated with clinical outcomes in patients
receiving adjuvant taxane-containing therapy for operable breast
cancer. J Clin Oncol. 30:3051–3057. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnson N, Johnson SF, Yao W, Li YC, Choi
YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, et
al: Stabilization of mutant BRCA1 protein confers PARP inhibitor
and platinum resistance. Proc Natl Acad Sci USA. 110:17041–17046.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Julka PK, Chacko RT, Nag S, Parshad R,
Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, et al: A phase
II study of sequential neoadjuvant gemcitabine plus doxorubicin
followed by gemcitabine plus cisplatin in patients with operable
breast cancer: Prediction of response using molecular profiling. Br
J Cancer. 98:1327–1335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Staudacher L, Cottu PH, Diéras V,
Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P,
Mignot L and Pierga JY: Platinum-based chemotherapy in metastatic
triple-negative breast cancer: The institut curie experience. Ann
Oncol. 22:848–856. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang K, Xie S, Ren Y, Xia H, Zhang X and
He J: Establishment of a bioluminescent MDA-MB-231 cell line for
human triple-negative breast cancer research. Oncol Rep.
27:1981–1989. 2012.PubMed/NCBI
|
|
26
|
Al Dhaheri Y, Eid A, AbuQamar S, Attoub S,
Khasawneh M, Aiche G, Hisaindee S and Iratni R: Mitotic arrest and
apoptosis in breast cancer cells induced by origanum majorana
extract: Upregulation of TNF-α and downregulation of survivin and
mutant p53. PLoS One. 8:e566492013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma CX, Cai S, Li S, Ryan CE, Guo Z,
Schaiff WT, Lin L, Lin L, Hoog J, Goiffon RJ, Prat A, et al:
Targeting CHK1 in p53-deficient triple-negative breast cancer is
therapeutically beneficial in human-in-mouse tumor models. J Clin
Invest. 122:1541–1552. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne
D, Chakrabarti A, Bosma T; kConFab Investigators, ; Fellowes A, et
al: Mutational profiling of familial male breast cancers reveals
similarities with luminal A female breast cancer with rare TP53
mutations. Br J Cancer. 111:2351–2360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Michils G, Hollants S, Dehaspe L, Van
Houdt J, Bidet Y, Uhrhammer N, Bignon YJ, Vermeesch JR, Cuppens H
and Matthijs G: Molecular analysis of the breast cancer genes BRCA1
and BRCA2 using amplicon-based massive parallel pyrosequencing. J
Mol Diagn. 14:623–630. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Murphy CG and Moynahan ME: BRCA gene
structure and function in tumor suppression: A repair-centric
perspective. Cancer J. 16:39–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oplustilova L, Wolanin K, Mistrik M,
Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A,
O'Connor MJ, et al: Evaluation of candidate biomarkers to predict
cancer cell sensitivity or resistance to PARP-1 inhibitor
treatment. Cell Cycle. 11:3837–3850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Choi DH, Lee MH, Bale AE, Carter D and
Haffty BG: Incidence of BRCA1 and BRCA2 mutations in young korean
breast cancer patients. J Clin Oncol. 22:1638–1645. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lord CJ and Ashworth A: Mechanisms of
resistance to therapies targeting BRCA-mutant cancers. Nat Med.
19:1381–1388. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mao XY, Fan CF, Zheng HC, Wei J, Yao F and
Jin F: p53 nuclear accumulation and ERalpha expression in ductal
hyperplasia of breast in a cohort of 215 chinese women. J Exp Clin
Cancer Res. 29:1122010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mao XY, Chen H, Wang H, Wei J, Liu C,
Zheng HC, Yao F and Jin F: MTA1 expression correlates significantly
with ER-alpha methylation in breast cancer. Tumour Biol.
33:1565–1572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao L, Wang L, Jin F, Ma W, Ren J, Wen X,
He M, Sun M, Tang H and Wei M: Silencing of estrogen receptor alpha
(ERalpha) gene by promoter hypermethylation is a frequent event in
Chinese women with sporadic breast cancer. Breast Cancer Res Treat.
117:253–259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin F, Liu C, Guo Y, Chen H and Wu Y:
Clinical implications of Girdin and PI3K protein expression in
breast cancer. Oncol Lett. 5:1549–1553. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sahab ZJ, Man YG, Byers SW and Sang QX:
Putative biomarkers and targets of estrogen receptor negative human
breast cancer. Int J Mol Sci. 12:4504–4521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pachmann K, Camara O, Kroll T, Gajda M,
Gellner AK, Wotschadlo J and Runnebaum IB: Efficacy control of
therapy using circulating epithelial tumor cells (CETC) as ‘liquid
biopsy’: Trastuzumab in HER2/neu-positive breast carcinoma. J
Cancer Res Clin Oncol. 137:1317–1327. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Soria JC, Blay JY, Spano JP, Pivot X,
Coscas Y and Khayat D: Added value of molecular targeted agents in
oncology. Ann Oncol. 22:1703–1716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
De P, Sun Y, Carlson JH, Friedman LS,
Leyland-Jones BR and Dey N: Doubling down on the PI3K-AKT-mTOR
pathway enhances the antitumor efficacy of PARP inhibitor in triple
negative breast cancer model beyond BRCA-ness. Neoplasia. 16:43–72.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Konishi H, Mohseni M, Tamaki A, Garay JP,
Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, et
al: Mutation of a single allele of the cancer susceptibility gene
BRCA1 leads to genomic instability in human breast epithelial
cells. Proc Natl Acad Sci USA. 108:17773–17778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sy SM, Huen MS and Chen J: PALB2 is an
integral component of the BRCA complex required for homologous
recombination repair. Proc Natl Acad Sci USA. 106:7155–7160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stefansson OA, Jonasson JG, Johannsson OT,
Olafsdottir K, Steinarsdottir M, Valgeirsdottir S and Eyfjord JE:
Genomic profiling of breast tumours in relation to BRCA
abnormalities and phenotypes. Breast Cancer Res. 11:R472009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Albarakati N, Abdel-Fatah TM, Doherty R,
Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N,
Seedhouse C, et al: Targeting BRCA1-BER deficient breast cancer by
ATM or DNA-PKcs blockade either alone or in combination with
cisplatin for personalized therapy. Mol Oncol. 9:204–217. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tommiska J, Bartkova J, Heinonen M,
Hautala L, Kilpivaara O, Eerola H, Aittomäki K, Hofstetter B, Lukas
J, von Smitten K, et al: The DNA damage signalling kinase ATM is
aberrantly reduced or lost in BRCA1/BRCA2-deficient and
ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 27:2501–2506.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Murria R, Palanca S, de Juan I, Egoavil C,
Alenda C, García-Casado Z, Juan MJ, Sánchez AB, Santaballa A,
Chirivella I, et al: Methylation of tumor suppressor genes is
related with copy number aberrations in breast cancer. Am J Cancer
Res. 5:375–385. 2014.PubMed/NCBI
|
|
48
|
Bueno RC, Canevari RA, Villacis RA,
Domingues MA, Caldeira JR, Rocha RM, Drigo SA and Rogatto SR: ATM
down-regulation is associated with poor prognosis in sporadic
breast carcinomas. Ann Oncol. 25:69–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiang H, Reinhardt HC, Bartkova J,
Tommiska J, Blomgvist C, Nevanlinna H, Bartek J, Yaffe MB and
Hemann MT: The combined status of ATM and p53 link tumor
development with therapeutic response. Genes Dev. 23:1895–1909.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chan KY, Ozcelik H, Cheung AN, Ngan HY and
Khoo US: Epigenetic factors controlling the BRCA1 and BRCA2 genes
in sporadic ovarian cancer. Cancer Res. 62:4151–4156.
2002.PubMed/NCBI
|
|
51
|
Haitjema A, Brandt BW, Ameziane N, May P,
Heringa J, de Winter JP, Joenje H and Dorsman JC: A protein
prioritization approach tailored for the FA/BRCA pathway. PLoS One.
8:e620172013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mote PA, Leary JA, Avery KA, Sandelin K,
Chenvix-Trench G, Kirk JA and Clarke CL: kConFab Investigators:
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are
associated with altered expression of estrogen-responsive proteins
and the predominance of progesterone receptor A. Genes Chromosomes
Cancer. 39:236–248. 2004. View Article : Google Scholar : PubMed/NCBI
|
